Literature DB >> 26933184

Lethal acute liver failure in a patient treated with sunitinib.

S S Guillen1, M Meijer2, F E de Jongh1.   

Abstract

Sunitinib is a tyrosine kinase inhibitor that is used as an anticancer drug in renal cell carcinoma (RCC), pancreatic neuroendocrine tumours (PNETs) and gastrointestinal stromal tumour. Elevated liver enzymes are frequently observed during treatment but acute liver failure is uncommon. We describe a case of fulminant acute liver failure and acute kidney injury during treatment with sunitinib for metastatic RCC. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26933184      PMCID： PMC4785412          DOI： 10.1136/bcr-2015-213624

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  8 in total

1.  Acute hepatic failure following monotherapy with sunitinib for ovarian cancer.

Authors:  A Taran; A Ignatov; B Smith; S D Costa; J Bischoff
Journal:  Cancer Chemother Pharmacol       Date:  2008-08-21       Impact factor: 3.333

2.  A clinical approach to pharmacogenetics.

Authors:  L C G de Graaff; R H N van Schaik; T van Gelder
Journal:  Neth J Med       Date:  2013-04       Impact factor: 1.422

3.  Causal or casual? The role of causality assessment in pharmacovigilance.

Authors:  R H Meyboom; Y A Hekster; A C Egberts; F W Gribnau; I R Edwards
Journal:  Drug Saf       Date:  1997-12       Impact factor: 5.606

4.  Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.

Authors:  Willmosh Mermershtain; Irena Lazarev; Noa Shani-Shrem; Samuel Ariad
Journal:  Clin Genitourin Cancer       Date:  2012-10-12       Impact factor: 2.872

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

6.  Sunitinib-related fulminant hepatic failure: case report and review of the literature.

Authors:  Eric W Mueller; Michelle L Rockey; Mitchell C Rashkin
Journal:  Pharmacotherapy       Date:  2008-08       Impact factor: 4.705

7.  Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis.

Authors:  Ezzeldin M Ibrahim; Ghieth A Kazkaz; Khaled M Abouelkhair; Ali M Bayer; Osama A Elmasri
Journal:  Int J Clin Oncol       Date:  2012-11-21       Impact factor: 3.402

8.  Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine.

Authors:  Amy M Weise; Chin Y Liu; Anthony F Shields
Journal:  Ann Pharmacother       Date:  2009-03-31       Impact factor: 3.154
  8 in total
  5 in total

1.  Diclofenac sex-divergent drug-drug interaction with Sunitinib: pharmacokinetics and tissue distribution in male and female mice.

Authors:  Chii Chii Chew; Salby Ng; Yun Lee Chee; Teng Wai Koo; Ming Hui Liew; Evelyn Li-Ching Chee; Pilar Modamio; Cecilia Fernández; Eduardo L Mariño; Ignacio Segarra
Journal:  Invest New Drugs       Date:  2017-03-11       Impact factor: 3.850

2.  Sunitinib-paracetamol sex-divergent pharmacokinetics and tissue distribution drug-drug interaction in mice.

Authors:  Ming Hui Liew; Salby Ng; Chii Chii Chew; Teng Wai Koo; Yun Lee Chee; Evelyn Li-Ching Chee; Pilar Modamio; Cecilia Fernández; Eduardo L Mariño; Ignacio Segarra
Journal:  Invest New Drugs       Date:  2017-01-09       Impact factor: 3.850

3.  Impaired clearance of sunitinib leads to metabolic disorders and hepatotoxicity.

Authors:  Qi Zhao; Ting Zhang; Xue-Rong Xiao; Jian-Feng Huang; Yan Wang; Frank J Gonzalez; Fei Li
Journal:  Br J Pharmacol       Date:  2019-05-07       Impact factor: 8.739

Review 4.  Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature.

Authors:  Hana Studentova; Jindriska Volakova; Martina Spisarova; Anezka Zemankova; Kvetoslava Aiglova; Tomas Szotkowski; Bohuslav Melichar
Journal:  BMC Gastroenterol       Date:  2022-02-05       Impact factor: 3.067

5.  An Insight on the Pathways Involved in Crizotinib and Sunitinib Induced Hepatotoxicity in HepG2 Cells and Animal Model.

Authors:  Lin Guo; Tingli Tang; Dongmei Fang; Hui Gong; Bikui Zhang; Yueyin Zhou; Leiyi Zhang; Miao Yan
Journal:  Front Oncol       Date:  2022-01-28       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.